Replies to post #30925 on Intellipharmaceutics International Inc. (IPCI)

[fabius]

Find out who they are

from the "Management discussion and analysis" - Q3

"Expenditures for R&D for the three months ended August 31, 2017 were higher by $665,654 compared to the three months ended August 31, 2016. The increase is primarily due to higher third party consulting fees associated with our preparation for the FDA Advisory Committee meeting in relation to our Oxycodone ER NDA filing."


Yes Odidi proved he is not skilled for CEO activities, but who the hell are those morons who took a LOT of money to get to a complete disaster at the AdComm ??